MA35433B1 - Anticorps anti-pcsk9 et leurs utilisations - Google Patents

Anticorps anti-pcsk9 et leurs utilisations

Info

Publication number
MA35433B1
MA35433B1 MA36818A MA36818A MA35433B1 MA 35433 B1 MA35433 B1 MA 35433B1 MA 36818 A MA36818 A MA 36818A MA 36818 A MA36818 A MA 36818A MA 35433 B1 MA35433 B1 MA 35433B1
Authority
MA
Morocco
Prior art keywords
antibodies
pck9
antigen
fragments
binding
Prior art date
Application number
MA36818A
Other languages
English (en)
Inventor
Julian Davies
Barrett Allan
Ryan James Darling
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA35433B1 publication Critical patent/MA35433B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Cette invention concerne des anticorps anti-proprotéine convertase subtilisine/kexine de type 9 (pcsk9), ou des fragments de ceux-ci se liant à l'antigène, des compositions contenant lesdits anticorps anti-pcsk9 ou fragments de ceux-ci se liant à l'antigène, et des méthodes les utilisant pour traiter l'hyperlipidémie ou l'hypercholestérolémie.
MA36818A 2011-09-16 2014-03-11 Anticorps anti-pcsk9 et leurs utilisations MA35433B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535625P 2011-09-16 2011-09-16
PCT/US2012/054737 WO2013039958A1 (fr) 2011-09-16 2012-09-12 Anticorps anti-pcsk9 et leurs utilisations

Publications (1)

Publication Number Publication Date
MA35433B1 true MA35433B1 (fr) 2014-09-01

Family

ID=46881177

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36818A MA35433B1 (fr) 2011-09-16 2014-03-11 Anticorps anti-pcsk9 et leurs utilisations

Country Status (28)

Country Link
US (1) US8530414B2 (fr)
EP (1) EP2756003A1 (fr)
JP (1) JP6013487B2 (fr)
KR (1) KR101607783B1 (fr)
CN (1) CN103781802B (fr)
AP (1) AP2014007499A0 (fr)
AR (1) AR087715A1 (fr)
AU (1) AU2012308786B2 (fr)
BR (1) BR112014005799A2 (fr)
CA (1) CA2845706C (fr)
CL (1) CL2014000590A1 (fr)
CO (1) CO6910164A2 (fr)
CR (1) CR20140087A (fr)
DO (1) DOP2014000041A (fr)
EA (1) EA024430B1 (fr)
EC (1) ECSP14013242A (fr)
GT (1) GT201400049A (fr)
IL (1) IL231282A0 (fr)
MA (1) MA35433B1 (fr)
MX (1) MX347475B (fr)
MY (1) MY168961A (fr)
PE (1) PE20141147A1 (fr)
SG (1) SG2014014187A (fr)
TN (1) TN2014000094A1 (fr)
TW (1) TWI586687B (fr)
UA (1) UA114604C2 (fr)
WO (1) WO2013039958A1 (fr)
ZA (1) ZA201401267B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
SI2668212T1 (en) 2011-01-28 2018-08-31 Sanofi Biotechnology, Human antibodies against PCSK9 for use in the treatment processes of certain groups of subjects
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US10058630B2 (en) * 2012-10-22 2018-08-28 Concievalve, Llc Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
EP2810955A1 (fr) 2013-06-07 2014-12-10 Sanofi Procédés pour inhiber l'athérosclérose par l'administration d'un inhibiteur de PCSK9
EP2862877A1 (fr) 2013-10-18 2015-04-22 Sanofi Procédés pour inhiber l'athérosclérose par l'administration d'un inhibiteur de PCSK9
WO2014197752A1 (fr) 2013-06-07 2014-12-11 Regeneron Pharmaceuticals, Inc. Méthodes d'inhibition de l'athérosclérose consistant à administrer un inhibiteur de la pcsk9
JP6267792B2 (ja) * 2013-06-28 2018-01-24 アムジエン・インコーポレーテツド ホモ接合性家族性高コレステロール血症の治療方法
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN105085684B (zh) * 2014-05-14 2020-04-17 上海亨臻实业有限公司 Pcsk9靶向重组疫苗设计及其应用
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
EP2975059A1 (fr) 2014-07-15 2016-01-20 Kymab Limited Anticorps pour utilisation dans le traitement de maladies liées à certains variants spécifiques de pcsk9 dans certaines populations spécifiques de patients
DE202015008974U1 (de) 2014-07-15 2016-06-30 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
DE202015009006U1 (de) 2014-07-15 2016-08-19 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
WO2016023916A1 (fr) 2014-08-12 2016-02-18 Kymab Limited Traitement de maladie par la liaison d'un ligand à des cibles présentant un intérêt
WO2016071701A1 (fr) 2014-11-07 2016-05-12 Kymab Limited Traitement de maladie par liaison de ligand à des cibles d'intérêt
CN107531798B (zh) 2015-03-20 2022-02-18 奥胡斯大学 Pcsk9的抑制剂用于脂蛋白代谢病症的治疗
CN107922507B (zh) 2015-08-18 2022-04-05 瑞泽恩制药公司 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
CN106810609A (zh) * 2015-11-27 2017-06-09 苏州君盟生物医药科技有限公司 抗pcsk9抗体及其应用
RU2739208C2 (ru) * 2015-12-31 2020-12-21 Цзянсу Хэнжуй Медицин Ко., Лтд. Анти-pcsk9 антитело, его антигенсвязывающий фрагмент и их медицинское применение
JP2019509714A (ja) * 2016-01-05 2019-04-11 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． Ｐｃｓｋ９抗体、その抗原結合フラグメント及び医薬用途
US20200165354A1 (en) * 2016-09-20 2020-05-28 WuXi Biologics Ireland Limited Novel Anti-PCSK9 Antibodies
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
JOP20190112A1 (ar) 2016-11-14 2019-05-14 Amgen Inc علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
CN108424457B (zh) * 2017-02-13 2021-06-01 成都金洛克锶生物技术有限公司 针对pcsk9抗体与检测试剂盒的制备及其用途
MX2019012083A (es) 2017-04-13 2019-11-21 Cadila Healthcare Ltd Nueva vacuna de peptidos contra la pcsk9.
AU2020209215B2 (en) 2019-01-18 2023-02-02 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
EP3969620A1 (fr) 2019-05-17 2022-03-23 Regeneron Pharmaceuticals, Inc. Procédés basés sur le génome pour réduire le risque cardiovasculaire
CN114369164A (zh) * 2020-10-15 2022-04-19 苏州君盟生物医药科技有限公司 抗pcsk9单克隆抗体的生产工艺

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512840A (ja) 1999-10-22 2003-04-08 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ラット脳に由来する核酸分子およびプログラム細胞死モデル
AU2001280471A1 (en) 2000-08-11 2002-02-25 Eli Lilly And Company Novel secreted proteins and their uses
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2008057457A2 (fr) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
CN101636179B (zh) 2006-11-07 2012-10-10 默沙东公司 Pcsk9拮抗剂
US20100150937A1 (en) 2006-11-07 2010-06-17 Sparrow Carl P Antagonists of pcsk9
US20100040610A1 (en) 2006-11-07 2010-02-18 Ayesha Sitlani Antagonists of pcsk9
MX2009010957A (es) 2007-04-13 2009-10-29 Novartis Ag Moleculas y metodos para modular la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9).
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP2205639B1 (fr) * 2007-10-26 2015-12-23 Merck Sharp & Dohme Corp. Anti-pcsk9 et méthodes de traitement de troubles du métabolisme lipidique et du cholestérol
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
US9994923B2 (en) 2008-04-23 2018-06-12 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 (PCSK9) variants and uses thereof
TWI516501B (zh) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2493505A4 (fr) 2009-10-30 2013-06-12 Merck Sharp & Dohme Antagonistes de la pcsk9 avec anticorps fab ax189 et ax1, et variantes afférentes
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
KR20120138241A (ko) * 2010-03-11 2012-12-24 화이자 인코포레이티드 ｐＨ 의존성 항원 결합을 갖는 항체

Also Published As

Publication number Publication date
IL231282A0 (en) 2014-04-30
MX2014003175A (es) 2015-03-05
CN103781802A (zh) 2014-05-07
CR20140087A (es) 2014-05-02
AR087715A1 (es) 2014-04-09
WO2013039958A1 (fr) 2013-03-21
ZA201401267B (en) 2015-11-25
CA2845706A1 (fr) 2013-03-21
AP2014007499A0 (en) 2014-03-31
CL2014000590A1 (es) 2014-10-17
TN2014000094A1 (en) 2015-07-01
BR112014005799A2 (pt) 2017-03-28
CA2845706C (fr) 2016-03-22
EP2756003A1 (fr) 2014-07-23
DOP2014000041A (es) 2014-06-30
TWI586687B (zh) 2017-06-11
JP6013487B2 (ja) 2016-10-25
AU2012308786B2 (en) 2016-12-15
AU2012308786A1 (en) 2014-02-27
SG2014014187A (en) 2014-05-29
NZ622393A (en) 2015-11-27
PE20141147A1 (es) 2014-09-22
MX347475B (es) 2017-04-27
UA114604C2 (uk) 2017-07-10
JP2014530188A (ja) 2014-11-17
KR20140044939A (ko) 2014-04-15
MY168961A (en) 2019-01-28
TW201323444A (zh) 2013-06-16
KR101607783B1 (ko) 2016-03-30
CN103781802B (zh) 2016-08-24
GT201400049A (es) 2015-05-28
EA024430B1 (ru) 2016-09-30
ECSP14013242A (es) 2014-07-31
US20130071405A1 (en) 2013-03-21
US8530414B2 (en) 2013-09-10
CO6910164A2 (es) 2014-03-31
EA201490470A1 (ru) 2014-06-30

Similar Documents

Publication Publication Date Title
MA35433B1 (fr) Anticorps anti-pcsk9 et leurs utilisations
PH12019501274A1 (en) Methods of treating or preventing cholesterol related disorders
CY1123250T1 (el) Σταθερα σκευασματα τα οποια περιεχουν anti-pcsk9 αντισωματα
MA49599B1 (fr) Anticorps spécifiques à cd47 et pd-l1
EA201391157A1 (ru) Антагонисты pcsk9
EA201992038A1 (ru) Анти-псф-тау-антитела и способы их применения
MA53356B1 (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
EA201592267A1 (ru) Способы ингибирования атеросклероза посредством введения ингибитора pcsk9
MA38176A1 (fr) Nouvel anticorps anti-hemagglutinine, utile pour le traitement, l'inhibition ou la prévention de l’infection virale a grippe a
PH12014501261A1 (en) Pcsk9 antagonists
PH12014501927A1 (en) Antibodies to matrix metalloproteinase 9
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
EA201690889A1 (ru) Режимы дозирования для применения ингибиторов pcsk9
MA38161A1 (fr) Anticorps anti-bmp-6
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9
UA103916C2 (en) Dkk-1 antibody
MA47221A1 (fr) Anticorps monoclonal à pd-l1
EA201390467A1 (ru) Композиции антител и способы применения
EA201491724A1 (ru) Антитела, нейтрализующие rsv, mpv и pvm, и их применения
EA201300138A1 (ru) Фармацевтическая композиция и метод ингибирования продукции или усиления элиминации белка p24
EA202192810A1 (ru) АНТИТЕЛА К PcrV, КОТОРЫЕ СВЯЗЫВАЮТ PcrV, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТИТЕЛА К PcrV, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
MA34487B1 (fr) Compositions d'anticorps anti-vegfr-3.
MA49607A1 (fr) Anticorps monoclonal pour il-5ra
MA35807B1 (fr) Procedes de traitement ou de prevention de troubles associés au cholesterol
EA201792576A1 (ru) Антитела, нейтрализующие rsv, mpv и pvm, и их применения